|
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies Clinical research trials and Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies. Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies clinical trial. Subjects frequently get the best healthcare possible for their Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies  Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
For Condition: Leukemia, Lymphocytic, Acute,Lymphoma, Low-Grade,Lymphoma, T-Cell,Leukemia, Lymphocytic, Chronic,Lymphoma, B-Cell
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 15 Years/60 Years
Genders: Both
Protocol Entry Criteria: - Patients with CLL, ALL, low grade Lymphoma, B and T cell Lymphoma of the intermediate and high grade (if not eligible for autologous transplant) CD52 expression of >20% by flow cytometry. - Patients in relapse after conventional treatment. - Patients with an HLA-identical or one-antigen mismatched sibling, or matched unrelated donor. - Patients previously exposed to Campath-1H treatment response. Patient must be at least 2 months or later from the last dose of Campath-1H.
Total Enrollment: 142
Location and Contact Information:
MDAnderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Donna Griffith 713-792-4230
Additional Information:
Study ID Numbers: ID99-410;
Study Start Date: April 2001
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038883
Other Lymphoma, Low-Grade Studies:
1. A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies
2. Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
3. Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG
4. Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
5. Phase II study of ONTAK in previously treated patients with low-grade Non-Hodgkin's Lymphoma (NHL)
Related Studies:
Other Lymphoma, Low-Grade Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
|
|
|
|
|
|
|
|
